Health Care·Pharmaceuticals·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.37 | N/A | +8.19% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.37 | N/A | +8.19% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on the company's ability to navigate market challenges. They emphasized their commitment to growth and innovation.
Management expressed satisfaction with the EPS performance despite not providing specific revenue figures.
They highlighted ongoing efforts to enhance product offerings and market presence.
The earnings report indicates that Prestige Consumer HE is performing well in terms of earnings per share, exceeding expectations by over 8%. The positive stock reaction of nearly 5% suggests that investors are encouraged by the company's performance, even without specific revenue figures. Management's focus on product enhancement and market strategy may contribute to future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EDWARDS LIFESCIENCES
Feb 4, 2013